ScholarX: CHOI, YOON LA

Detailed Information

CHOI, YOON LA (최윤라)

Medicine (Medicine)

Research Area

Tel 02-3410-2797
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Epidermal growth factor receptor:13||Immunohistochemistry:12||Lung cancer:10||lung cancer:10||Mutation:9||PDL1:9||Adenocarcinoma:8||lung adenocarcinoma:8||Lung adenocarcinoma:8||nonsmall cell lung cancer:8||prognosis:8||Carcinoma:7||EGFR:7||Nonsmall cell lung cancer:7||Prognosis:6||Liposarcoma:6||Anaplastic lymphoma kinase:6||Breast cancer:6||ALK:6||NSCLC:6||immunohistochemistry:5||Lung neoplasms:5||EGFR mutation:5||adenocarcinoma:5||KRAS:5||nextgeneration sequencing:5||HER2:5||MET:4||Nextgeneration sequencing:4||mutation:4||gastric cancer:4||epidermal growth factor receptor:4||biomarker:4||Nonsmallcell lung cancer:4||Esophageal squamous cell carcinoma:4||Non–small cell lung cancer:4||metastasis:4||immunotherapy:4||PDL1 expression:4||Tyrosine kinase inhibitor:3||Immunotherapy:3||Circulating tumor DNA:3||Targeted therapy:3||CD24:3||esophageal squamous cell carcinoma:3||Squamous cell carcinoma:3||Epidermal growth factor receptor (EGFR):3||breast cancer:3||Precision medicine:3||FISH:3||PIK3CA:3||cMET:3||Chemotherapy:3||Anticancer drug:3||ROS1:3||Biomarker:3||colorectal cancer:3||targeted therapy:3||T790M:3||TGFB:3||NTRK fusion:3||Soft tissue sarcoma:3||Metastatic breast cancer:3||recurrencefree survival:2||Metastasis:2||BRAF:2||Immunomodulation:2||TRK inhibitors:2||Adenocarcinoma of lung:2||Chemoradiotherapy:2||Pazopanib:2||Pemetrexed:2||Peptide nucleic acids:2||Pleomorphic carcinoma:2||siRNA:2||Populationbased:2||small cell lung cancer:2||Translocation:2||fluorescent in situ hybridization:2||Intestinal metaplasia:2||Triplenegative breast cancer:2||squamous cell carcinoma:2||Predictive factor:2||HER2 mutation:2||Molecular subtype:2||Tumorigenesis:2||Progesterone receptor:2||Molecular targeted therapy:2||Prognostic biomarkers:2||CT:2||histologic grade:2||HER3:2||HGVS nomenclature:2||hydatidiform mole:2||Breast neoplasms:2||triplenegative breast cancer:2||Pulmonary pleomorphic carcinoma:2||Estrogen receptor:2||RET fusion:2||vandetanib:2||RET rearrangement:2||NUT carcinoma:2||RNAbased NGS assay:2||liposarcoma:2||liquid biopsy:2||<:2||Circulating tumor cells:2||Laboratory correlates:2||National health insurance:2||lung neoplasms:2||Anaplastic lymphoma kinase (ALK):2||Neoadjuvant chemoradiotherapy:2||Leptomeningeal metastases:2||Receptor:2||breast:2||Claims data:2||methylation:2||Recurrence:2||Histologic transformation:2||Nivolumab:2||Liquid biopsy:2||Histology:2||Nonsmallcell lung carcinoma:2||Lung:2||cervical cancer:2||choriocarcinoma:2||Observer variation:2||circulating tumor DNA:2||SPOP protein:2||nonsmall cell lung cancer (NSCLC):2||nonsmallcell lung:2||nonsmallcell lung cancer:2||Sarcoma:2||non–small cell lung cancer:2||Fibroblast growth factor receptor 1:2||BRCA1:2||Colorectal cancer:2||2DE:2||ALKrearranged NSCLC:2||Gankyrin:2||Gastric carcinoma:2||MDM2:2||pancreas:2||MET exon 14 skipping:2||IDH1:2||patientderived xenograft:2||peptide nucleic acids:2||Gastric dysplasia:2||Cellfree DNA:2||ITGB3:2||Squamous cell:2||PET:2||PET/CT:2||Standardized uptake value:2||polymerase chain reaction:2||Endometrial carcinoma:2||Endometrial hyperplasia:2||predictor:2||Survival:2||Ceritinib:2||Merkel cell carcinoma:2||Genomic profiling:2||programmed deathligand 1:2||prostate cancer:2||Asian:2||ductal adenocarcinoma:2||TFE3:2||radiotherapy:2||HER2breast cancer:1||HER2overexpressing breast cancer:1||HER2positive (HR/HER2+) breast cancer:1||HM61713:1||HMGA2:1||HOXB9:1||HPV DNA chip typing:1||HR plus:1||Hemangiopericytoma:1||Hematologic malignancy:1||Her2:1||Her2:1||Heterogeneity:1||Histologic Transformation:1||Histological type:1||Histones:1||Homologous recombination repair deficiengy (HRD):1||Hormone receptor:1||Hormone receptor negative:1||Hormone receptorpositive breast cancer:1||Human recombinant TRAIL:1||Hydatidiform mole:1||IASLC criteria for invasion:1||ICDO3:1||IDH2:1||IFN:1||IRS2:1||Imatinib:1||Immune Checkpoint Inhibitors:1||Immune checkpoint inhibitor:1||Immune checkpoint inhibitors:1||Immune responserelated genes (igenes):1||Immunerelated adverse event:1||Immunohistochemistry:1||Immunology:1||In situ hybridization:1||In situ hybridization, f:1||In situ hybridization, fluorescence:1||Inflammation:1||Inte:1||Intrapulmonary spread:1||Invasion:1||Invasive mediastinal nodal staging:1||Invasive mucinous adenocarcinoma:1||Junction sequence of the fusion gene:1||KIAA1217:1||KIAA1217RET fusion:1||KRAS gene:1||KRAS gene mutation:1||KRAS mutations:1||Ki67:1||Ki67 proliferation index:1||Kirsten rat sarcoma viral oncogene homolog (KRAS):1||LRRK2:1||LYN:1||Lepidic:1||Leukocytespecific protein 1:1||Limitedstage:1||LncRNA:1||Local therapy:1||Locally advanced nonsmall cell lung cancer:1||Lung squamous cell carcinoma:1||Lymph Node Tuberculosis:1||Lymph node assessment:1||Lymph nodes:1||Lymphangioleiomyomatosis:1||Lymphocytes, TumorInfiltrating:1||Lymphoma, large Bcell diffuse:1||MAID:1||MET inhibitor:1||MGMT:1||Magnetic resonance imaging:1||Malignant mixed mullerian tumors (MMMT):1||Management:1||Master observational trial:1||Mediastinum:1||Melanoma:1||Merkel cell polyoma virus:1||Merkel cell polyomavirus:1||Mesenchymalepithelial transtion tyrosine kinase receptor:1||Met:1||Metabolic tumor volume:1||Microarray data and Actinomycin D:1||Microinvasive carcinoma:1||Micropapillary:1||Microsatellite instability:1||MitoRAISE:1||Mitochondrial function:1||Molecular change:1||Molecular diagnosis and prognosis:1||Molecular diagnostic techniques:1||Molecular diagnostics:1||Molecular pathology:1||Molecular sequencing:1||Molecular tumor board:1||Mucoepidermoid:1||Multimodality:1||N:1||N2:1||NAB2STAT6:1||NEUROD1:1||NKX21:1||NR1D1:1||NUT:1||NUT Carcinoma:1||NUT midline carcinoma:1||NUTM1 fusion gene:1||Nanostring:1||Neoadjuvant:1||Neoplasm metastasis:1||Neuroblastoma:1||Neuroectodermal tumor:1||Nonadenocarcinoma:1||Nonsmall cell l:1||Nonsmall cell lung cancer (NSCLC):1||Nonsmall cell lung carcinoma:1||Nonsmallcell lung:1||Nonsquamous nonsmall cell lung cancer:1||Non–smallcell lung cancer (NSCLC):1||OS:1||Oesophageal squamous cell carcinoma:1||Oligorecurrence:1||Oncogene:1||Oncogenic driver:1||Osimertinib:1||Ovarian epithelial cancer:1||Ovary:1||Overall survival:1||Oxaliplatinresistance:1||P:1||PD1 blockade:1||PD1 inhibitor:1||PD1 inhibitors:1||PDL1 inhibitors:1||PDL1 score:1||PDX:1||PEComa:1||PF06463922:1||POU2F3:1||PTEN:1||Pa:1||Palbociclib:1||Palliative chemotherapy:1||Pancreatic ductal adenocarcinoma:1||Papillomavirus, human:1||Paradoxical Response:1||Paraspinal muscle:1||Pathogenes:1||Pathologic tumor stage:1||Patient derived Xenograft:1||Patientderived cells:1||Patientderived xenograft:1||Patientderived xenograft model:1||Pelvis:1||Pembrolizumab:1||Pneumonectomy:1||Preclinical model:1||Predictive value of tests:1||Predictivity:1||Predictor:1||Prevalence:1||Progn:1||Prognostic factor:1||Prognostic marker:1||Prognostic markers:1||Prognostic model:1||Programmed cell death 1 protein:1||Programmed cell deathligand 1:1||Programmed deathligand 1:1||Proliferationrelated genes (pgenes):1||Prophylactic cranial irradiation:1||Prostate cancer:1||Quintuplenegative:1||Quintuplenegative breast cancer:1||RASSF1:1||RET:1||RET/PTC gene rearrangement:1||RRM2:1||RTPCR:1||Radiation therapy:1||Radiosensitizer:1||Radiotherapy:1||Realtime polymerase chai:1||Realworld data:1||Receptor fibroblast growth factor, type 3:1||Relapse pattern:1||Relapsefree survival:1||Relative mitochondrial ATP synthesis rate:1||Repeat biopsy:1||Reproducibility:1||Resection margin:1||Residents:1||Resistance mechanism:1||Rheumatoid arthritis:1||Ring test:1||Risk assessment:1||Risk of distant metastasis:1||SCLC:1||SEC31A:1||SLC22A18:1||SP263:1||SRC:1||Second primary lung cancer:1||Sentinel lymph node biopsy:1||Smads:1||Small cell carcinoma:1||Small cell lung cancer:1||Small cell lung cancer (SCLC):1||Small cell lung carcinoma:1||Smallcell lung cancer:1||Smoothened protein:1||Sof:1||Soft tissue neoplasms:1||Solid:1||Solidity:1||Solitary fibrous tumor:1||Solitary fibrous tumors:1||Somatic copy number alteration:1||Somatic mutations:1||Spatial transcriptomics:1||Squamous cell lung cancer:1||Stage III:1||Structural variations:1||Subrenal capsule implantation:1||Surgery:1||Survival outcomes:1||Synovial sarcoma:1||Synovitis:1||Synthetic lethality:1||T790M mutation:1||TITF1:1||TM4SF4:1||TNBC:1||TP53:1||TPR:1||TRK immunohistochemistry:1||TSC2 gene:1||TTF1:1||Targeted sequencing:1||Temozolomide:1||Therapeutic target:1||Thymidine phosphorylase:1||Thymidylate synthase:1||Thyroid:1||Thyroid gland:1||Training:1||Transforming growth factor beta:1||Transitional cell:1||Triple negative breast cancer (TNBC):1||Trophoblast:1||Tuberous sclerosis complex:1||Tumor Biomarkers:1||Tumor burden:1||Tumor mutation burden:1||Tumour mutation burden:1||Tyrosine:1||Tyrosine kinase inhibitor (TKI):1||UBE2C:1||UPS:1||Urinary bladder:1||Uterine cervical neoplasms:1||Volumebased:1||WNT/TCF pathway:1||Whole exome sequencings:1||Whole transcriptome sequencing:1||Wholegenome sequencing:1||Xray computed tomography:1||Xenograft model:1||Xenograftassociated lymphoproliferative disease:1||YAP1:1||YES:1||aCGH:1||adenocarcinoma of lung:1||adipogenesis:1||adjvuant therapy:1||airdried FNA specimen:1||amphiregulin:1||amplification:1||apoptosis:1||atypical leiomyoma:1||basallike:1||bile duct:1||biomarkers:1||borderline:1||brain metastases:1||brain metastasis:1||cMET inhibitor (ABN401):1||cMYC:1||ckit:1||cmet:1||calpain 6:1||calpain 6 protein:1||cancer cells:1||capillary:1||carcinosarcoma:1||cell adhesion molecule:1||cell cycle:1||cell cycle inhibitors:1||cell migrati:1||central nervous system:1||cervical intraepithelial neoplasia:1||childhood:1||chro:1||chromogenic in situ hybridization:1||circulating tumor cells:1||circulatingtumor DNA:1||cisplatin (CDDP) chemotherap:1||claudin:1||claudin4:1||clear cell carcinoma:1||clinicopathologic feature:1||colon cancer:1||colonic polyps:1||colorectal adenoma:1||combination therapy:1||combined treatment:1||comprehensive genomic profiling:1||computational biology:1||concordance:1||concurrent chemoradiotherapy:1||consolidation therapy:1||copy number variation:1||criteria:1||crizotinib:1||ctDNA:1||cyclin D1:1||dasatinib:1||dedifferentiated liposarcoma:1||dedifferentiated liposarcoma:1||dermatofibrosarcoma protuberans:1||desmoid:1||desmoid tumor:1||diagnosis:1||diagnostic biomarker:1||diagnostics:1||differentiated thyroid carcinoma:1||domainII:1||domainT:1||dovitinib:1||driver mutation:1||dual energy CT:1||durvalumab:1||dysplasia:1||early breast cancer:1||early stage:1||en bloc nephrectomy:1||endocrinetumors:1||endometrium:1||endoscopic ultrasoundguided fine needle aspiration:1||epidermal growth factor:1||epidermal growth factor receptor mutation:1||epidermal growth factor receptortyrosine kinase inhibitors (EGFRTKIs):1||epigenetic derepression:1||epithelial cell adhesion molecule (EpCAM):1||epithelial tumor:1||erlotinib:1||esophagectomy:1||esophagus:1||estrogen:1||expression microarray:1||expression profiling:1||fibroblast growth factor receptor 1 (FGFR1) amplification:1||fibromatosis:1||fluorescence:1||follicular:1||fusion gene:1||gastric carcinoma:1||gastritis:1||gene amplification:1||gene fusion:1||genetic alterations:1||genetic translocation:1||genomic profiling:1||gliomatosis cerebri:1||hedgehog proteins:1||hemangioma:1||herpes simplex virusthymidine kinase:1||heterogeneity:1||histological grade:1||histone modification:1||homologydependent recombination deficiency:1||human leukocyte antigen:1||human monoclonal antibody:1||human papillomavirus:1||hyperplasia:1||inflammatory myofibroblastic tumor:1||intensitymodulated radiation therapy:1||interchangeability:1||intestinal metaplasia:1||intraabdominal liposarcoma:1||intraductal tubulopapillary neoplasm:1||intratumoral heterogeneity:1||invasion:1||kras:1||leiomyoma:1||lepidic:1||lineagespecific oncogene:1||liver metastasis:1||local tumor control:1||locoregional recurrence:1||lowdose CT screening:1||lung:1||lung adenocarcinoma subgroup:1||lymph node metastasis:1||magnetic:1||magnetic resonance imaging:1||mechanical ventilation:1||mesenchymal stromal cells:1||metabolic tumor volume:1||metastatic breast cancer:1||methylated DNA immunoprecipitationbisulphite sequencing:1||miRNA:1||microarray:1||midline carcinoma:1||molecular epidemiology:1||molecular pathology:1||molecular profiling:1||molecular profilingguided therapy:1||molecular subtype:1||molecular tumor board:1||mtDNA copy number:1||multiple pulmonary nodules:1||mutations:1||myomectomy:1||nanorheology:1||natural course:1||neoadjuvant chemotherapy:1||neversmoker:1||neversmoker female:1||next generation sequencing:1||next generation sequencing (NGS):1||nonHodgkin&apos:1||nonsmall cell lung carcinoma:1||nonsmall cell lung cancer:1||nuclear protein in testis (NUT):1||oncotype DX recurrence score:1||osimertinib:1||ovarian serous neoplasms:1||ovarian tumor:1||ovary:1||p14ARFMDM2p53 pathway:1||p16:1||p53:1||panTRK immunohistochemistry:1||papillary thyroid carcinoma:1||papillary thyroid carcinoma (PTC):1||patched receptors:1||pathology:1||patientderived xenograft (PDX) models:1||pemetrexed:1||peripheral:1||peripheral nervous system neoplasm:1||pharmacodynamics:1||pharmacokinetics:1||phenylethanolamine Nmethyltransferase:1||pheochromocytoma/paraganglioma:1||plasmonic:1||plateletderived growth factor beta:1||platinum chemotherapy:1||potential cancerpromoting genes:1||precision medicine:1||precision oncology:1||primitive:1||progno:1||prognostic biomarker:1||prognostic facto:1||prognostic factor:1||protein:1||pure groundglass nodule:1||quantitative image variables:1||radial:1||radial nerve:1||radiomics:1||rectal neoplasm:1||refractory metastatic breast cancer:1||reliability:1||reproducibility:1||resection margins:1||residual kidney function:1||respiratory failure.:1||retroperitoneal liposarcoma:1||retroperitoneal sarcoma:1||retroperitoneal soft tissue sarcoma:1||retroperitoneal space:1||risk classification:1||ros1:1||s lymphoma:1||sarcoma:1||seminal vesicle:1||serous neoplasms:1||serrated polyp:1||sigmoid colon perforation:1||single nucleotide variant:1||smallcell lung cancer:1||solid tumors:1||solitary pulmonary nodule:1||sonic hedgehog:1||sonic hedgehog protein:1||squamous cell lung cancer:1||squamous esophageal cancer:1||stemness:1||stomach:1||subtype:1||surgical excision:1||survival:1||survival outcome:1||survivin:1||syphilis:1||tamoxifen:1||targeted deep sequencing:1||targeted exome sequencing:1||targeted sequencing:1||tight junction:1||tissue expansion devices:1||total lesion glycolysis:1||total mesorectal excision:1||transcriptome analysis:1||transducer of ErbB2:1||trastuzumab:1||tremelimumab:1||treponema pallium:1||triplenegative:1||trophoblast:1||tumor:1||tumor mutation burden:1||tumor suppressor gene:1||tyrosine kinase domain mutation:1||tyrosine kinase inhibitor:1||tyrosine kinase inhibitors:1||uterine cancers:1||uterine cervical neoplasms:1||viscosity:1||welldifferentiated liposarcoma:1||wild type:1||xenograft:1||young:1||1p19q:1||22C3:1||= 1 cm Invasive breast cancer:1||= 1 cm i:1||ADPS EGFR Mutation Test Kit:1||ALK fusion:1||ALK fusion genes:1||ALK testing:1||ALKtyrosine Kinase Inhibitor:1||ALKtyrosine kinase inhibitor:1||APAF1:1||ASCL1:1||ATP:1||Abdomen:1||Adjuvant:1||Adjuvant treatment:1||Advanced breast cancer:1||Afatinib:1||Alternative splicing:1||Alveolar soft part sarcoma:1||Amplification:1||Anaplastic:1||Anaplastic Lymphoma Kinase:1||Anaplastic gliomas:1||Anaplastic large cell lymphoma kinase:1||Angiomyolipoma:1||Artificial intelligence:1||Asian population:1||BRAF V600E:1||BRAF mutation:1||BRAF(V600E) mutation:1||BRAFV600E:1||BRD4NUT fusion oncogene protein:1||Basallike breast cancer:1||Behavior code:1||Biomarker testing turnaround time:1||Biomarkers:1||Biopsy:1||Bmi1:1||Brain metastases:1||Bronchi:1||Cmet inhibitor:1||Cmet receptor:1||C797S mutation:1||CC chemokine:1||CD151:1||CD34:1||CD8 expression:1||CDK4:1||CIP2A:1||CISH:1||CNS metastases:1||CTNNB1:1||Calpain 6 protein:1||Cancer Systems Biology:1||Capecitabine:1||Carcinoma, nonsmallcell lung:1||Carcinoma, papillary:1||Carcinosarcoma:1||Cell cycle inhibitor:1||Cell cycle regulator:1||Cervical cancer:1||Cervical carcinoma:1||Cervical intraepithelial neoplasia:1||Cervical spine:1||Characteristic:1||Chemotherapy resistance:1||Chimeric transcripts:1||Chip:1||Choriocarcinoma:1||Cigarette smoking:1||Cisplatin:1||Coexpression:1||Cold coagulation:1||Combination treatment:1||Companion diagnostics:1||Comprehensive cancer panel assay:1||Concurrent Chemoradiation therapy (CCRT):1||Consensus:1||Consolidationtotumor ratio:1||Copy number:1||Crizotinib:1||Cyclin D1:1||Cytology:1||DDIT3:1||DDLPS:1||DFS:1||DNA amplification:1||DNA copy number alterations:1||DNA methylation:1||DNA methylation analysis:1||DNA repair gene upregulation:1||DNA repair pathway:1||DNA sequencing:1||DR5:1||DR5 dependent apoptosis:1||Dedifferentiated and welldifferentiated form:1||Deep learning:1||Dendritic cell sarcoma:1||Dermatofibroma:1||Dermatofibrosarcoma:1||Dermatofibrosarcoma protuberans:1||Detection methods:1||Diffusion magnetic resonance imaging:1||Digital pathology:1||Discoidin domain receptor 2:1||Driver genes:1||Droplet digital PCR:1||Drug resistance:1||Durvalumab:1||E6:1||E7:1||EBUSTBNA:1||EGER messenger RNA (mRNA):1||EGFR exon20 insertion:1||EGFR gene:1||EGFR mutations:1||EGFR testing:1||EGFR tyrosine kinase inhibitor:1||EGFRTKI treatment:1||EGFRmutation:1||EML4ALK:1||EMT:1||ER:1||ER status:1||ERBB2:1||ERK:1||Early stage:1||Electrosurgical conization:1||Endoscopic ultrasoundguided fine needle aspiration:1||Endosonography:1||Engraftment:1||Engrailed 1:1||Enhancer hijacking:1||Epidermal growth:1||Epidermal growth factor:1||Epidermal growth factor receptor exon 20 insertion mutations:1||Epidermal growth factor receptor tyrosine kinase inhibitor:1||Epithelialmesenchymal transition:1||EpsteinBarr virus infections:1||ErbB receptors:1||Esophageal cancer:1||Esophageal neoplasms:1||Exon 20 insertion:1||Exon deletion:1||Extranodal:1||F18Fluorodeoxyglucose:1||FDG PET/CT:1||FGFR:1||Fibrous dysplasia:1||Fluorescent in situ hybridization:1||Fusion:1||GNAS:1||GalNAcT14:1||Gene amplification:1||Gene expression profiling:1||GenesWell BCT score:1||Genetic translocation:1||Genomic landscape:1||Genomic profile:1||Genomics:1||Girdin:1||Gli protein:1||Groundglass opacity:1||HER pathway:1||HER2:1||HER2 amplification:1||

STATISTICS: Total View:; Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE